Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Encorafenib - Array BioPharma/Ono Pharmaceutical/Pierre Fabre

Next Previous
Drug Profile

Encorafenib - Array BioPharma/Ono Pharmaceutical/Pierre Fabre

Alternative Names: BRAFTOVI; LGX-818; NVP-LGX818; NVP-LGX818-NXA; ONO-7702; PF 07263896; W-0090

Latest Information Update: 20 Mar 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Novartis Pharmaceuticals Corporation
  • Developer Array BioPharma; German Cancer Research Center; Merck KGaA; National Cancer Institute (USA); Novartis Pharmaceuticals Corporation; Ono Pharmaceutical; Pfizer; Pierre Fabre; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; University of Heidelberg
  • Class Amines; Antineoplastics; Carbamates; Chlorinated hydrocarbons; Fluorinated hydrocarbons; Pyrazoles; Pyrimidines; Small molecules; Sulfonamides
  • Mechanism of Action Proto oncogene protein b raf inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Malignant melanoma
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Colorectal cancer; Malignant melanoma
  • Registered Non-small cell lung cancer
  • Preregistration Thyroid cancer
  • Phase II Brain metastases; Glioma; Haematological malignancies; Multiple myeloma; Solid tumours
  • Phase I Cancer

Most Recent Events

  • 08 Mar 2024 Pierre Fabre completes a Phase-III clinical trials in Malignant melanoma (Adjuvant therapy, Combination therapy) in Italy (PO) (EudraCT2021-000743-41)
  • 28 Nov 2023 Ono Pharmaceutical plans to file regulatory submissions for Colorectal cancer (Combination therapy, First-line therapy) in Japan (PO), by 2024
  • 02 Nov 2023 Efficacy data from a phase II PHAROS trial in Non-small cell lung cancer released by Pierre Fabre
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top